Iohexol Icg Farma (Iohexol)

Iohexol contains a high density of iodine atoms that absorb X‑ray photons. When administered, it distributes within the vascular or cerebrospinal spaces, creating radiodense outlines of vessels and organs. This increased attenuation allows imaging equipment to produce detailed pictures of internal anatomy.

The dose of Iohexol Icg Farma is determined by the prescribing clinician based on the specific imaging study, patient weight, renal function, and the route of administration. Healthcare professionals calculate the appropriate volume to achieve optimal contrast enhancement while minimizing risk.

The safety of Iohexol during pregnancy or lactation has not been definitively established. It should be used only when clearly needed, after a careful risk‑benefit assessment by the treating physician. Women who are pregnant or breastfeeding should discuss alternatives with their healthcare provider.

To order Iohexol Icg Farma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iohexol is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality while reducing the incidence of discomfort and adverse reactions, making it a preferred choice for many radiographic procedures.

Iohexol Icg Farma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture, and extreme temperature fluctuations to maintain its stability and sterility.

Iohexol Icg Farma is administered by a qualified healthcare professional via intra‑arterial, intravenous, or intrathecal injection, depending on the imaging study. The exact route, injection rate, and volume are determined by the prescribing clinician and the imaging protocol.

Serious risks include severe allergic reactions (anaphylaxis), acute kidney injury, especially in patients with pre‑existing renal impairment, and rare neurotoxic events. Prompt recognition and management of these reactions are essential, and patients should be monitored closely during and after administration.

Iohexol Icg Farma should be avoided in patients with a known hypersensitivity to iodinated contrast media, severe renal insufficiency where alternative imaging is possible, and in individuals who have experienced prior severe reactions to similar agents. Clinicians must evaluate each patient’s medical history before use.